Bold Business Logo

Next Stop for the Billionaire Space Race: The Moon

In recent months, several of the world’s top billionaires have made headlines in relation to the quest for space. Elon Musk, founder of SpaceX was awarded a NASA contract for the Human Landing System program. Sir Richard Branson traveled along with a small crew to the outer edges of space in Virgin Galactic’s Unity22. (Read more about Branson crossing the finish line of the billionaire space race in this Bold story.) Jeff Bezos, founder of Blue Origin, followed Branson’s accomplishment just a week later. Based on this, it’s clear that a billionaire space race exists. And the next stage in this race involves a competition for providing lunar services.

As part of the Artemis Project, NASA has big plans to reestablish lunar services in the coming years. But unlike NASA programs in the past, they are increasingly relying on commercial services to achieve their goals. One of these services involves developing a lunar lander as part of the Human Landing System program. And those in the billionaire space race are jockeying for position to be selected for the advancing these lunar services. Of course, that’s where things are getting a bit complicated. This not only pertains to those in the billionaire space race but also for NASA as well.

“Instead of investing in two competing lunar landers as originally intended, the Agency chose to confer a multi-year, multi-billion-dollar head start to SpaceX. The decision broke the mold of NASA’s successful commercial space programs by putting an end to meaningful competition for years to come.” – Jeff Bezos, Founder of Blue Origin

Recent Developments in the Billionaire Space Race

The Human Landing System, as part of NASA’s Artemis Project, hopes to resume lunar services as early as 2024. But in order to achieve this, it must develop not only space travel to and from the moon. It similarly will need a lunar lander to facilitate transportation to and from the moon. Rather than awarding contracts for such a design that NASA would own, NASA is taking a different approach. It is instead awarding contracts to companies that would create and own the lunar services. It would then lease these services from these companies to fulfill its missions.

Understandably, such contracts could be highly lucrative, earning companies billions of dollars. This is one of the factors that has incentivized the billionaire space race. Three major companies were interested in attaining these NASA contracts, which included Blue Origin, SpaceX and Dynetics. In April of 2021, NASA announced that the contract would be awarded to SpaceX solely, which didn’t go over well with the other applicants. As a result, both Blue Origin and Dynetics have filed complaints with the General Accountability Office in hopes of changing NASA’s decision.

“[The House Appropriations Committee] urges NASA to bolster competition in lander development and production and improve the United States’ prospects for landing astronauts on the Moon in 2024.” – July 15th House Appropriations Committee Report

Competition for Lunar Services Heating Up

The reason that both Dynetics and Blue Origin lodge a complaint against NASA involves its selection of a single contractor. In previous comments, NASA stated it planned on selecting 2 lunar services contractors in an effort to promote competition. This would invite greater innovation while also potentially lowering costs. Thus, when NASA selected SpaceX, it contradicted prior commitments. In all fairness, SpaceX’s bid of $2.89 billion was far less than the others. Blue Origin’s bid price was almost $6 billion. But for those in the billionaire space race, this did not justify a solo-selection on just one company.

A dude driving his buggy around the moon like a champ
The billionaire space race was won by Sir Richard Branson, but who wins the next phase and is the first to get to the moon?

NASA’s dilemma at present is primarily a financial one. It had originally requested a budget of $3.4 billion from Congress for 2021. However, it only received approval for $850 million. This naturally limited the number of contracts it might award for lunar services. Because SpaceX provided a means to allow NASA to work within their budget, they were selected. But now, Bezos has developed a counteroffer that might also help NASA’s tight money position. He has promised to reduce his landing services bid by $2 billion and self-fund a pathfinder mission as well. This makes Blue Origin’s offer much more attractive, showing how competition in the billionaire space race can be beneficial.

“The big thing here is that we’re starting to work more closely with the commercial community. [The Commercial Lunar Payload Services program] is our first step on that front.” –  Jake Bleacher, Chief Exploration Scientist at NASA

A New Approach to Lunar Services and Space Travel

At the present time, NASA is facing challenges from several directions. Notably, it must defend its decisions to choose SpaceX alone in front of the General Accountability Office. The GAO’s decision in this matter is expected in early August. NASA also faces financial constraints, and is involved in negotiations with Congress over future budgets. In recent months, both the Senate and the House Appropriations Committee voted to advance funding for space and other lunar services. But Congress also strongly encouraged NASA to award contracts to more than one company in order to invite competition. As the pressure related to the billionaire space race heats up, NASA will need to resolve these issues.

Faced with these pressures, NASA has already embraced different strategies related to lunar services. In other lunar services contracts, NASA is allowing commercial entities the right to develop and own their products. NASA then simply pays for the use of these products and other services as they need them. For example, under the Commercial Lunar Payload Services (CLPS) program, fourteen companies have received NASA contracts. NASA could certainly do the same with SpaceX, Blue Origin, and Dynetics if it chose. Given its limited budget, this seems like a rational approach. And for those in the billionaire space race, they would likely welcome such a situation.

Advancing Private-Public Partnerships

NASA’s decision to increase its reliance on commercial enterprises has fueled the billionaire space race significantly. Given the development of lunar services is pricey, it’s understandable that billion-dollar companies and individuals will compete in this area. This approach reduces expenses for NASA, especially if it embraces a lunar-travel-as-a-service mentality. And it also encourages greater innovations by private industry less constrained by government bureaucracies. It’s clear that NASA wants to return to the moon as soon as possible. And it seems several billionaires are happy to help.

 

Defining diversity, equity and inclusion for business can be difficult – get the free six-page handout that can help put you on the right track!

The Next Phase of Fighting COVID-19 – COVID Treatment Pills

The situation with COVID-19 has been a fluid one from the beginning. The coronavirus emerged rapidly, introducing the world to its first global pandemic in decades. Hundreds of thousands have since died from the virus, despite efforts in quarantining, mask-wearing, and social distancing. COVID vaccines then appeared and offered significant protection against COVID-19 infection and spread. But these appear to require ongoing boosters over time. And the new delta variant of the coronavirus seems to have reduced its overall effectiveness to a degree.

Understanding this, it’s clear that our battle with COVID-19 is far from over. This realization has prompted researchers to forge ahead in their efforts to develop new treatment methods. One of these endeavors involves finding an oral tablet for COVID-19 that can be used alongside other therapies. Thus, COVID treatment pills are being tested by a number of pharmaceutical companies. An oral tablet for COVID-19 could not only increase access to management for millions. It could also offer new ways to reduce virus spread and impact. Many therefore hope that COVID treatment pills could be a step closer in getting the world back to normal.

“There is an increasing realization that we will not be able to fully vaccinate the global population as fast as we would like to or should.” – Sam Fazeli, Head of EMEA Research, Bloomberg Intelligence; Non-executive Director at Arecor Limited

COVID Treatment Pills Versus Vaccines

Several vaccines are currently on the market that are designed to prevent infection of the coronavirus and its spread. Pfizer, Moderna, and Johnson & Johnson are among the major ones available for many nations. These vaccines work by different mechanisms, but in essence, they attempt to prevent infection by the virus from the start. By developing specific antibodies against the virus or its machinery, COVID-19 is unable to effectively infect human cells. But while this is ideal, personal resistance to vaccination and limited access have reduced the potential for success. An oral table for COVID-19 could solve some of these issues.

Unlike vaccines, an oral tablet for COVID-19 would not likely introduce an antibody attack against the virus. Instead, the COVID treatment pills being developed today take a different approach to interrupts the virus’ life cycle. Some target enzymes needed to help the virus reproduce itself within human cells. Others insert false RNA messages into the virus’ genome that also prevents normal replication. Thus, while vaccines offer upfront protection, an oral tablet for COVID-19 limits its potency afterwards. These are key distinctions between the two forms of medical biotechnology treatments. (Medical biotechnology is the future–read why in this Bold story.) And its why using one will not deter the use of the other.

“We learned very quickly in HIV that if you don’t pay attention to [ongoing viral resistance], you develop molecules that quickly become obsolete.” – Daria Hazuda, Chief Scientific Officer, Merck Research Center

Developing an Oral Tablet for COVID-19 with Lasting Effects

Coronavirus is not the first virus where researchers have attempted to develop oral therapy. Such efforts have certainly taken place in fighting HIV as well as other viruses like Ebola. In these efforts, researchers have learned a great deal in addition to spending billions of dollars. In fact, many of the effective HIV treatments today came from this research, which is guiding current work with COVID. (Dive deeper into the innovations in HIV treatments with this Bold story.) Researchers are much more aware of how quickly a virus can adapt and change as a result. Therefore, their efforts in developing COVID treatment pills strives to interfere with the virus in ways that aren’t easily avoided.

Currently, scientists hope the leading COVID treatment pills being developed will have lasting effectiveness. Those that inhibit enzymes that help the virus reproduce use a major common pathway that would be hard to work around. Others that insert false genetic material limit viral resistance because of the major changes they make in viral activities. Whether this proves to be true or not is yet to be known. But researchers recognize that any oral tablet for COVID-19 must be effective despite efforts of the coronavirus to continually adapt.

“…It is relatively easier to make these drugs than it is to produce vaccines and biologics, and the wherewithal to do so exists across the world…And easier manufacturing should lead to lower pricing that can help speed distribution to the most vulnerable populations.” – Sam Fazeli

Leading Pharmaceutical Manufacturers for Oral Therapies

At the current time, there are three major pharmaceutical companies actively pursuing an oral tablet for COVID-19. These include Pfizer, Merck, and Japan-based Shionogi. All are either actively involved in experimental trials for their drugs or will be soon. Any or all of these COVID treatment pills may therefore be available within months.

  • Pfizer – The oral tablet for COVID-19 being developed by Pfizer works by blocking a protease enzyme. This enzyme is needed by the coronavirus to replicate itself within cells. If the tablet is taken within 5 days of infection, it should limit the virus’ ability to spread through the body. As a result, infections would be less indurated and less severe. Pfizer’s current COVID treatment pills would be taken twice daily.
  • Merck – The name of Merck’s oral tablet for COVID-19 is molnupiravir, and it works by a different mechanism. This drug inserts false RNA genetic material into the coronavirus’s genome, causing errors in replication. Merck, which is working with Ridgeback Biotherapeutics, has a contract with the FDA in place. It will provide 1.7 million treatments for $1.2 billion, which is roughly $700 per patient.
  • Shionogi – This pharmaceutical firm is small but well known. It developed the now popular cholesterol drug, Crestor. Now, it is pursuing an oral tablet for COVID-19 that can be taken only once daily. This drug will work similar to the one being developed by Pfizer as it also disrupts cellular protease activity. Shionogi may also partner with a larger company, like Astra-Zeneca, for global distribution once ready for market.
An old dude trying to open a child-proof pill bottle
An oral tablet for COVID-19 treatment? There may be some soon available.

A New Therapy Against COVID Needed

In addition to opposition against vaccinations and new COVID variants, additional barriers to effective treatment exist. Many developing countries have limited access to vaccines. Cost of development of vaccines and other hospital-based therapies are additional obstacles. The addition of COVID treatment pills to these therapy options would therefore be welcomed. This is especially true if they were less expensive, easy to administer, and limited in duration. Hopefully, drug trials will demonstrate that oral COVID treatment pills will be both safe and effective. If so, an oral tablet for COVID-19 may soon be part of routine course of care.

 

Defining diversity, equity and inclusion for business can be difficult – get the free six-page handout that can help put you on the right track!

Indoor Gardening Companies Offer a Brighter and Sustainable Future

Over the last several years, there have been some notable trends related to dieting and food selections. Many people have shifted toward a plant-based diet due to health reasons. Others have embraced these foods because they offer a more sustainable approach to meeting population needs. At the same time, there has been a heightened concern about organic diets and food safety. Each of these trends have convinced many to invest in their own home gardens. And a fair number have explored hydroponic farming as a way to do this in an affordable yet convenient way.

Hydroponic farming itself is defined as a way to grow plants through the use of water, minerals and other nutrients. Indoor farming, however, takes a broader approach, with many indoor systems providing more classic seed-and-soil products. Both types of practices have recently increased in popularity, especially in the aftermath of the pandemic. With lockdowns and quarantines in place, some decided to see if they actually had a green thumb. Much to their surprise, they realized a variety of companies now exist that make indoor farming a breeze.

“People are paying attention to food, and they care about what they eat. Then the global pandemic played a part in this, with people leaning into growing their own food.” – Hank Adams, Founder and CEO of Rise Gardens

The Current State of Indoor Farming

In the past, someone who wanted to attempt an indoor garden had their work cut out for them. They would need to buy pots, seeds, shelving, soil, fertilizer and more before starting this endeavor. Then, after all was in place, care and constant attention had to be provided to yield favorable results. Of course, not everyone had such great luck, despite their best effort. Buying foods from the local grocery store was much less challenging, and usually less expensive, in the long run. This was the state of affairs before hydroponic farming and indoor gardening advanced.

Today, hydroponic farming and indoor gardening make these activities simple and productive. The majority of these systems provide customers with various types of pods or trays where the plants will grow. Not only do these kits contain everything a person might need. But they also take up small amounts of space and are quite efficient. At the same time, most also utilize smart technologies to assist people with the tasks of gardening. Apps and alerts let people know when plants need additional nutrients, fertilizer, water and light. Some even provide automated technologies that ensure proper timing of these tasks.

“I am absolutely convinced we are going to see in the coming two years a total disruption in the way we grow things.” – FX Rouxel, Founder and CEO of Gardyn

Notable Indoor Gardening Companies

 There are a number of startups that are taking the market by storm. Both hydroponic farming and indoor gardening systems have enjoyed notable growth. With this in mind, the following are few of the top businesses in this industry at the current time.

  • Rise Gardens – This Chicago-based startup has raised a total of $13 million since its founding in 2017. Sales of its IoT-connected, smart indoor gardening systems have exceeded seven figures this last year. And Rise Garden prides itself on systems designed to enhance one’s household décor.
  • AeroGarden – This company represents the largest indoor farming business in this sector. Likewise, it offers a variety of products ranging from seed kits to lighting systems as well as hydroponic farming equipment. And systems range in price from $30 to $300 to meet a variety of needs and tastes.
  • AeroGrow – This Boulder-based startup was recently purchased by Scott’s Miracle Grow for $40 million. As an indoor gardening system manufacturer, it saw its sales triple in 2020. Given this, the buy-out was not a big surprise, especially since Scott’s already owned 80% of the company’s stock.
  • Click and Grow – This indoor farming producer launched in 2014 via Kickstarter. Its smart soil plant pods come in 70 different varieties. Also, its patented tray systems provide an easy modular assembly that can be stacked up to 3 levels high. With plant pods averaging around $2 each, this too is a very economical system.

“With the impact of population growth and the demand on our natural resources, it is inevitable for us to become more self-sufficient. I believe we are all going to be growing some of our food at home soon and I’m certain we’ve developed the best solution to do just that.” – Mattias Lepp, Founder and CEO of Click & Grow

A cartoon of a woman growing her own jungle
There are a multitude of benefits indoor gardening provides–not the least of which is a nicer living space.

The Appeal of Indoor Gardening

When it comes to indoor farming, current systems offer many benefits. There now quite easy to assemble and monitor, and automated controls and alerts streamline tasks. In addition, hydroponic farming and indoor gardens produce good yields. In fact, most companies provide guarantees that their systems will produce a certain number of vegetables, herbs, and more. Plus, these systems are aesthetically pleasing and take up little space. This, as well as their affordability, have helped create a significant appeal for consumers.

At the same time, indoor gardening systems address some major concerns that many people share today. With expanding population numbers, scarcity of foodstuffs are real threats to humankind. This is especially concerning given global warming, climate change, and reductions in agricultural land. Mass production of food often uses chemicals and non-organic approaches to farming. Hydroponic farming and indoor gardening offer solutions to these problems as well. It’s therefore little wonder why these systems have increased in demand.

 

Defining diversity, equity and inclusion for business can be difficult – get the free six-page handout that can help put you on the right track!

How can we help?

Bold Business
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.